D. Garceau

1.6k total citations
35 papers, 1.1k citations indexed

About

D. Garceau is a scholar working on Physiology, Molecular Biology and Psychiatry and Mental health. According to data from OpenAlex, D. Garceau has authored 35 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Physiology, 7 papers in Molecular Biology and 6 papers in Psychiatry and Mental health. Recurrent topics in D. Garceau's work include Alzheimer's disease research and treatments (9 papers), Dementia and Cognitive Impairment Research (6 papers) and Respiratory and Cough-Related Research (4 papers). D. Garceau is often cited by papers focused on Alzheimer's disease research and treatments (9 papers), Dementia and Cognitive Impairment Research (6 papers) and Respiratory and Cough-Related Research (4 papers). D. Garceau collaborates with scholars based in Canada, United States and United Kingdom. D. Garceau's co-authors include Daniel Saumier, Paul Aisen, Serge Gauthier, Nathalie Chauret, Denis Haine, John S. Sampalis, Anh Duong, Julie Laurin, Richard Briand and Francine Gervais and has published in prestigious journals such as New England Journal of Medicine, Journal of the American College of Cardiology and Neurology.

In The Last Decade

D. Garceau

34 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. Garceau Canada 15 661 349 330 174 138 35 1.1k
Carsten Hofmann Switzerland 17 623 0.9× 481 1.4× 356 1.1× 169 1.0× 213 1.5× 43 1.3k
Hui Pei China 18 392 0.6× 209 0.6× 454 1.4× 53 0.3× 71 0.5× 50 1.4k
Ritushree Kukreti India 25 291 0.4× 156 0.4× 464 1.4× 68 0.4× 317 2.3× 70 1.5k
Christine Bergmann United States 7 756 1.1× 159 0.5× 378 1.1× 185 1.1× 102 0.7× 17 1.2k
James R. Bonham United Kingdom 21 232 0.4× 489 1.4× 468 1.4× 209 1.2× 46 0.3× 60 1.4k
Guizhu Hong China 12 321 0.5× 201 0.6× 732 2.2× 75 0.4× 69 0.5× 18 1.4k
Michael Tanen United States 14 659 1.0× 307 0.9× 972 2.9× 55 0.3× 61 0.4× 21 2.2k
Brigitte Leininger‐Muller France 17 468 0.7× 92 0.3× 417 1.3× 43 0.2× 47 0.3× 29 1.3k
William Gottschalk United States 22 501 0.8× 73 0.2× 866 2.6× 49 0.3× 93 0.7× 41 1.4k

Countries citing papers authored by D. Garceau

Since Specialization
Citations

This map shows the geographic impact of D. Garceau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Garceau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Garceau more than expected).

Fields of papers citing papers by D. Garceau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Garceau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Garceau. The network helps show where D. Garceau may publish in the future.

Co-authorship network of co-authors of D. Garceau

This figure shows the co-authorship network connecting the top 25 collaborators of D. Garceau. A scholar is included among the top collaborators of D. Garceau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Garceau. D. Garceau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Garceau, D. & Nathalie Chauret. (2019). BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. Pulmonary Pharmacology & Therapeutics. 56. 56–62. 76 indexed citations
3.
Saumier, Daniel, Paul Aisen, Serge Gauthier, et al.. (2009). Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: The Alzhemedtm (Tramiprosate) experience. The journal of nutrition health & aging. 13(4). 370–372. 25 indexed citations
4.
Gauthier, Serge, Paul Aisen, Steven H. Ferris, et al.. (2009). Effect of tramiprosate in patients with mild-to-moderate alzheimer's disease: Exploratory analyses of the MRI sub-group of the alphase study. The journal of nutrition health & aging. 13(6). 550–557. 107 indexed citations
5.
Saumier, Daniel, Anh Duong, Denis Haine, D. Garceau, & John S. Sampalis. (2009). Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase study. The journal of nutrition health & aging. 13(9). 808–812. 41 indexed citations
6.
Dember, Laura M., Philip N. Hawkins, Bouke P. C. Hazenberg, et al.. (2007). Eprodisate for the Treatment of Renal Disease in AA Amyloidosis. New England Journal of Medicine. 356(23). 2349–2360. 172 indexed citations
7.
Aisen, Paul, Serge Gauthier, Bruno Vellas, et al.. (2007). Alzhemed: A Potential Treatment for Alzheimers Disease. Current Alzheimer Research. 4(4). 473–478. 87 indexed citations
8.
Aisen, Paul, Richard Briand, Daniel Saumier, et al.. (2007). Targeting Amyloid with Tramiprosate in Patients with Mild-to-Moderate Alzheimer Disease. 3(1). 111–125. 4 indexed citations
9.
Butrimienė, İrena, Bouke P. C. Hazenberg, Philip N. Hawkins, et al.. (2007). Beneficial effect of eprodisate (NC-503) on the preservation of kidney function in AA amyloidosis patients : 3-year follow-up results. UCL Discovery (University College London). 66. 248–248. 1 indexed citations
10.
Aisen, Paul, Daniel Saumier, Richard Briand, et al.. (2006). A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease. Neurology. 67(10). 1757–1763. 155 indexed citations
11.
Greenberg, Steven M., Jonathan Rosand, Alexander Schneider, et al.. (2006). A Phase 2 Study of Tramiprosate for Cerebral Amyloid Angiopathy. Alzheimer Disease & Associated Disorders. 20(4). 269–274. 32 indexed citations
12.
Garceau, D., et al.. (1995). Pharmacodynamics and pharmacokinetics of clentiazem and diltiazem in closed-chest anesthetized dogs. Cardiovascular Drugs and Therapy. 9(5). 685–692. 3 indexed citations
13.
Lepage, Guy, et al.. (1994). Clentiazem, Diltiazem, and Cold Cardioplegia in Isolated Ischemic Rabbit Hearts. Journal of Cardiovascular Pharmacology. 24(6). 950–959. 4 indexed citations
14.
Dumont, Louis, Huifang Chen, Pierre Daloze, Dasheng Xu, & D. Garceau. (1993). IMMUNOSUPPRESSIVE PROPERTIES OF THE BENZOTHIAZEPINE CALCIUM ANTAGONISTS DILTIAZEM AND CLENTIAZEM, WITH AND WITHOUT CYCLOSPORINE, IN HETEROTOPIC RAT HEART TRANSPLANTATION. Transplantation. 56(1). 181–184. 15 indexed citations
15.
Waters, David D. & D. Garceau. (1993). A dose-response study of clentiazem, a chloro-derivative of diltiazem, in patients with stable angina. Journal of the American College of Cardiology. 21(4). 964–970. 3 indexed citations
16.
Gaspo, Rania, et al.. (1992). Effects of clentiazem (TA-3090) and nifedipine on basal circulating catecholamine levels and on stimulation-evoked adrenal catecholamine secretion in anesthetized dogs. Canadian Journal of Physiology and Pharmacology. 70(7). 983–989. 2 indexed citations
17.
Lévy, Émile, Lesley Smith, Louis Dumont, et al.. (1992). The Effect of a New Calcium Channel Blocker (TA-3090) on Lipoprotein Profile and Intestinal Lipid Handling in Rodents. Experimental Biology and Medicine. 199(1). 128–135. 4 indexed citations
18.
Tardif, Jean‐Claude, Paola Russo, François Lavigne, et al.. (1991). Effect of clentiazem on lipid profile, lipoprotein composition and aortic fatty streaks in cholesterol-fed rabbits. Atherosclerosis. 90(2-3). 141–148. 2 indexed citations
19.
Lefebvre, Marc, et al.. (1989). High-performance liquid chromatographic method for the assay of TA-3090 and its pharmacokinetic parameters in healthy volunteers. Journal of Pharmaceutical and Biomedical Analysis. 7(12). 1919–1924. 5 indexed citations
20.
Garceau, D., Anthony W. Ford‐Hutchinson, & S. Charleson. (1987). 5-Lipoxygenase inhibitors and allergic conjunctivitis reactions in the guinea-pig. European Journal of Pharmacology. 143(1). 1–7. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carsten Hofmann Breakdown of academic impact, for papers by Hui Pei Breakdown of academic impact, for papers by Ritushree Kukreti Breakdown of academic impact, for papers by Christine Bergmann Breakdown of academic impact, for papers by James R. Bonham Breakdown of academic impact, for papers by Guizhu Hong Breakdown of academic impact, for papers by Michael Tanen Breakdown of academic impact, for papers by Brigitte Leininger‐Muller Breakdown of academic impact, for papers by William Gottschalk
Rankless by CCL
2026